Anbogen Therapeutics, Inc.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Anbogen’s drug pipeline features two lead small‑molecule candidates: “ABT‑101,” a tyrosine kinase inhibitor targeting HER2 exon20 insertion mutations in non‑small cell lung cancer; and “ABT‑301,” an HDAC1/2/3 inhibitor designed for combination therapy wit
The content above was translated by Ai
Founded Year
2019
Unified Business No.
82833776
Status
Active
Number of Employees
0
Total Paid-in
Capital
1,145,133,597 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2026)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Anbogen Therapeutics, Inc. is a Taipei‑based clinical‑stage biotech company focused on developing precision oncology drugs, with a mission to transform outcomes for cancer patients through innovative therapies.
The content above was translated by Ai
